Literature DB >> 23649624

Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.

Elena Chertova1, Cristina Bergamaschi, Oleg Chertov, Raymond Sowder, Jenifer Bear, James D Roser, Rachel K Beach, Jeffrey D Lifson, Barbara K Felber, George N Pavlakis.   

Abstract

Interleukin-15 (IL-15), a 114-amino acid cytokine related to IL-2, regulates immune homeostasis and the fate of many lymphocyte subsets. We reported that, in the blood of mice and humans, IL-15 is present as a heterodimer associated with soluble IL-15 receptor α (sIL-15Rα). Here, we show efficient production of this noncovalently linked but stable heterodimer in clonal human HEK293 cells and release of the processed IL-15·sIL-15Rα heterodimer in the medium. Purification of the IL-15 and sIL-15Rα polypeptides allowed identification of the proteolytic cleavage site of IL-15Rα and characterization of multiple glycosylation sites. Administration of the IL-15·sIL-15Rα heterodimer reconstituted from purified subunits resulted in sustained plasma IL-15 levels and in robust expansion of NK and T cells in mice, demonstrating pharmacokinetics and in vivo bioactivity superior to single chain IL-15. These identified properties of heterodimeric IL-15 provide a strong rationale for the evaluation of this molecule for clinical applications.

Entities:  

Keywords:  CD8+ T Cells; Glycosylation; HEK293 Human Cell; HPLC; Heterodimeric Cytokine; Interleukin; Interleukin-15; Natural Killer (NK) Cell; Proteolytic Cleavage; T Cell

Mesh:

Substances:

Year:  2013        PMID: 23649624      PMCID: PMC3689953          DOI: 10.1074/jbc.M113.461756

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.

Authors:  Thomas A Stoklasek; Kimberly S Schluns; Leo Lefrançois
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

2.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Authors:  Mark E Dudley; James C Yang; Richard Sherry; Marybeth S Hughes; Richard Royal; Udai Kammula; Paul F Robbins; JianPing Huang; Deborah E Citrin; Susan F Leitman; John Wunderlich; Nicholas P Restifo; Armen Thomasian; Stephanie G Downey; Franz O Smith; Jacob Klapper; Kathleen Morton; Carolyn Laurencot; Donald E White; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  Structural and biophysical studies of the human IL-7/IL-7Ralpha complex.

Authors:  Craig A McElroy; Julie A Dohm; Scott T R Walsh
Journal:  Structure       Date:  2009-01-14       Impact factor: 5.006

Review 4.  Twelve immunotherapy drugs that could cure cancers.

Authors:  Martin A Cheever
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

5.  Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

Authors:  Mathieu Epardaud; Kutlu G Elpek; Mark P Rubinstein; Ai-ris Yonekura; Angelique Bellemare-Pelletier; Roderick Bronson; Jessica A Hamerman; Ananda W Goldrath; Shannon J Turley
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

6.  How a cytokine is chaperoned through the secretory pathway by complexing with its own receptor: lessons from interleukin-15 (IL-15)/IL-15 receptor alpha.

Authors:  Erwin H Duitman; Zane Orinska; Elena Bulanova; Ralf Paus; Silvia Bulfone-Paus
Journal:  Mol Cell Biol       Date:  2008-05-27       Impact factor: 4.272

7.  Crystal structure of the IL-15-IL-15Ralpha complex, a cytokine-receptor unit presented in trans.

Authors:  Mami Chirifu; Chiharu Hayashi; Teruya Nakamura; Sachiko Toma; Tsuyoshi Shuto; Hirofumi Kai; Yuriko Yamagata; Simon J Davis; Shinji Ikemizu
Journal:  Nat Immunol       Date:  2007-07-22       Impact factor: 25.606

8.  Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity.

Authors:  Cristina Bergamaschi; Margherita Rosati; Rashmi Jalah; Antonio Valentin; Viraj Kulkarni; Candido Alicea; Gen-Mu Zhang; Vainav Patel; Barbara K Felber; George N Pavlakis
Journal:  J Biol Chem       Date:  2007-11-30       Impact factor: 5.157

9.  Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action.

Authors:  Sigrid Dubois; Hiral J Patel; Meili Zhang; Thomas A Waldmann; Jürgen R Müller
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

10.  IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation.

Authors:  Erwan Mortier; Tammy Woo; Rommel Advincula; Sara Gozalo; Averil Ma
Journal:  J Exp Med       Date:  2008-05-05       Impact factor: 14.307

View more
  51 in total

1.  Effect of Anti-IL-15 Administration on T Cell and NK Cell Homeostasis in Rhesus Macaques.

Authors:  Maren Q DeGottardi; Afam A Okoye; Mukta Vaidya; Aarthi Talla; Audrie L Konfe; Matthew D Reyes; Joseph A Clock; Derick M Duell; Alfred W Legasse; Amit Sabnis; Byung S Park; Michael K Axthelm; Jacob D Estes; Keith A Reiman; Rafick-Pierre Sekaly; Louis J Picker
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

2.  In Vivo Activation of Human NK Cells by Treatment with an Interleukin-15 Superagonist Potently Inhibits Acute In Vivo HIV-1 Infection in Humanized Mice.

Authors:  Kieran Seay; Candice Church; Jian Hua Zheng; Kathryn Deneroff; Christina Ochsenbauer; John C Kappes; Bai Liu; Emily K Jeng; Hing C Wong; Harris Goldstein
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

3.  Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques.

Authors:  Viraj Kulkarni; Margherita Rosati; Jenifer Bear; Guy R Pilkington; Rashmi Jalah; Cristina Bergamaschi; Ashish K Singh; Candido Alicea; Bhabadeb Chowdhury; Gen-Mu Zhang; Eun-Young Kim; Steven M Wolinsky; Wensheng Huang; Yongjun Guan; Celia LaBranche; David C Montefiori; Kate E Broderick; Niranjan Y Sardesai; Antonio Valentin; Barbara K Felber; George N Pavlakis
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

Review 4.  Cytokines in the Treatment of Cancer.

Authors:  Kevin C Conlon; Milos D Miljkovic; Thomas A Waldmann
Journal:  J Interferon Cytokine Res       Date:  2018-06-11       Impact factor: 2.607

5.  Efficient production and purification of recombinant human interleukin-12 (IL-12) overexpressed in mammalian cells without affinity tag.

Authors:  Srinivas Jayanthi; Bhanu prasanth Koppolu; Sean G Smith; Rashmi Jalah; Jenifer Bear; Margherita Rosati; George N Pavlakis; Barbara K Felber; David A Zaharoff; Thallapuranam Krishnaswamy Suresh Kumar
Journal:  Protein Expr Purif       Date:  2014-08-11       Impact factor: 1.650

6.  IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells.

Authors:  Fella Tamzalit; Isabelle Barbieux; Ariane Plet; Julie Heim; Steven Nedellec; Sébastien Morisseau; Yannick Jacques; Erwan Mortier
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

7.  Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.

Authors:  Spencer Ng; Jiusheng Deng; Raghavan Chinnadurai; Shala Yuan; Andrea Pennati; Jacques Galipeau
Journal:  Cancer Res       Date:  2016-08-03       Impact factor: 12.701

8.  IL-15 Agonists: The Cancer Cure Cytokine.

Authors:  Jennifer Wu
Journal:  J Mol Genet Med       Date:  2013-10-28

9.  Efficient production and enhanced tumor delivery of engineered extracellular vesicles.

Authors:  Dionysios C Watson; Defne Bayik; Avinash Srivatsan; Cristina Bergamaschi; Antonio Valentin; Gang Niu; Jenifer Bear; Mitchell Monninger; Mei Sun; Aizea Morales-Kastresana; Jennifer C Jones; Barbara K Felber; Xiaoyuan Chen; Ihsan Gursel; George N Pavlakis
Journal:  Biomaterials       Date:  2016-07-06       Impact factor: 12.479

10.  IL-15/IL-15Rα/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice.

Authors:  Yimin Shi; Lillia Dincheva-Vogel; Charles E Ayemoba; Jeffrey P Fung; Cristina Bergamaschi; George N Pavlakis; Farzin Farzaneh; Karin M L Gaensler
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.